- Home
- TAL vs PTCT Comparison
TAL vs PTCT Comparison
Compare TAL & PTCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TAL
- PTCT
- Stock Information
- Founded
- TAL 2003
- PTCT 1998
- Country
- TAL China
- PTCT United States
- Employees
- TAL N/A
- PTCT N/A
- Industry
- TAL Other Consumer Services
- PTCT Biotechnology: Pharmaceutical Preparations
- Sector
- TAL Real Estate
- PTCT Health Care
- Exchange
- TAL Nasdaq
- PTCT Nasdaq
- Market Cap
- TAL 6.4B
- PTCT 5.3B
- IPO Year
- TAL 2010
- PTCT 2013
- Fundamental
- Price
- TAL $10.92
- PTCT $68.51
- Analyst Decision
- TAL Buy
- PTCT Buy
- Analyst Count
- TAL 4
- PTCT 14
- Target Price
- TAL $12.66
- PTCT $67.00
- AVG Volume (30 Days)
- TAL 4.2M
- PTCT 1.2M
- Earning Date
- TAL 10-30-2025
- PTCT 11-06-2025
- Dividend Yield
- TAL N/A
- PTCT N/A
- EPS Growth
- TAL 91.79
- PTCT N/A
- EPS
- TAL 0.17
- PTCT 7.72
- Revenue
- TAL $2,411,045,000.00
- PTCT $1,764,929,000.00
- Revenue This Year
- TAL $33.28
- PTCT $120.26
- Revenue Next Year
- TAL $23.64
- PTCT N/A
- P/E Ratio
- TAL $62.70
- PTCT $8.89
- Revenue Growth
- TAL 47.99
- PTCT 96.00
- 52 Week Low
- TAL $8.50
- PTCT $35.51
- 52 Week High
- TAL $15.30
- PTCT $69.26
- Technical
- Relative Strength Index (RSI)
- TAL 50.51
- PTCT 72.99
- Support Level
- TAL $10.14
- PTCT $64.35
- Resistance Level
- TAL $11.28
- PTCT $67.24
- Average True Range (ATR)
- TAL 0.39
- PTCT 2.18
- MACD
- TAL -0.07
- PTCT 0.15
- Stochastic Oscillator
- TAL 59.88
- PTCT 93.46
About TAL TAL Education Group
TAL Education Group is a smart learning solutions provider in China. It operates a few business lines including enrichment learning, high school academic tutoring, learning technology, and content solutions. Among those business lines, TAL focuses on enrichment learning and content solutions.
About PTCT PTC Therapeutics Inc.
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company views its operations and manages its business in one operating segment: life science.